Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio, Inc.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Atlas Venture

New Enterprise Associates

Alexandria Venture Investments

Wu Capital

MP Healthcare Venture Management

Surveyor Capital

Cormorant Asset Management

Qiming Venture Partners USA

Monashee Investment Management

Invus

Verition Fund Management

Fidelity

Point72

Sixty Degree Capital

Fidelity Management and Research Company

We’re pleased to announce that Korro Bio will be attending the TD Cowen 44th Annual Health Care Conference in Boston.

Our Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Monday, March 4, 2024, at 2:10 PM ET.

Tune in for a live webcast of the presentation at: https://ir.korrobio.com/

https://lnkd.in/eT4CnDQr

#KorroBio #TDCowen #TDCowenHealthCare Cowen Inc.

#ICYMI, the Korro team attended the Nasdaq Closing Bell Ringing Ceremony on Tuesday. Thank you to Nasdaq for hosting us and your collaboration. Our team had an incredibly humbling moment celebrating our success.

Here's to Korro’s ongoing innovation as we advance #RNAediting.

Missed the livestream? Catch the recording here: https://lnkd.in/eZkjHPRS 

#KorroBio #ClosingBell

We are pleased to announce the key highlights from our presentation at the J.P. Morgan Healthcare Conference last week. We shared data for our lead program in Alpha-1 Antitrypsin Deficiency (AATD) and our pipeline.  

To read more about our recent accomplishments, see the full press release: bit.ly/3HncrAX

To view our corporate presentation, go to: https://bit.ly/3vEWOCx 

#JPM2024 #JPMorganHealthcare #KorroBio

We invite you to tune in to the live webcast today at 11:15 am PT / 2:15 pm ET. Our CEO and President, Ram Aiyar, will share the corporate update at the J.P. Morgan Healthcare Conference. Learn more about our progress in expanding the frontiers of genetic medicines through #RNAediting.

To view the presentation, visit: bit.ly/41VtvHN

To listen to the webcast, go to: https://lnkd.in/g4n4jJqk

Vineet Agarwal Steve Colletti

#JPMorganHealthcare #JPM2024 #KorroBio

	Dec '21	Dec '22	Dec '23
revenue	14.07M -
cost of revenue	3.84M -	2.51M 34.63%	3.63M 44.56%
gross profit	10.23M -	-2.51M 124.55%	-3.63M 44.56%
selling and marketing expenses
general and administrative expenses	11.69M -	16.80M 43.70%	27.28M 62.43%
selling general and administrative expenses	11.69M -	16.80M 43.70%	27.28M 62.43%
research and development expenses	23.80M -	42.20M 77.28%	57.25M 35.66%
other expenses	13.54M -	976K 92.79%	3.39M 247.23%
cost and expenses	35.49M -	59.00M 66.22%	84.53M 43.28%
operating expenses	35.49M -	59.00M 66.22%	84.53M 43.28%
interest expense		118K -
ebitda	-33.90M -	-56.49M 66.63%	-80.90M 43.23%
operating income	-35.49M -	-59.00M 66.22%	-84.53M 43.28%
depreciation and amortization	1.59M -	2.51M 57.43%	3.63M 44.56%
total other income expenses net	13.54M -	976K 92.79%	3.39M 247.23%
income before tax	-21.96M -	-58.02M 164.25%	-81.14M 39.85%
income tax expense	2K -	10K 400%	27K 170%
net income	-21.96M -	-58.03M 164.27%	-81.17M 39.87%
weighted average shs out	8.00M -	8.00M 0%	1.53M 80.89%
weighted average shs out dil	8.00M -	8.00M 0%	1.53M 80.89%
eps	-2.74 -	-7.25 164.60%	-53.08 632.14%
epsdiluted	-2.74 -	-7.25 164.60%	-53.08 632.14%

KRRO

COM:KORROBIO

Korro Bio

Last Close

50.62

22/11 21:00

Market Cap

385.94M

Beta: -

Volume Today

67.40K

Avg: -

Preview